Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial
暂无分享,去创建一个
K. Anstrom | E. Braunwald | G. Felker | Adrian F. Hernandez | M. Redfield | B. Bart | M. Givertz | Omar F. AbouEzzeddine | Kerry L Lee | Horng H. Chen | Adrian F. Hernandez | Kerry L. Lee | Horng H. Chen | K. Anstrom | Bradley A. Bart | Margaret M. Redfield | M. Redfield
[1] V. Hasselblad,et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). , 2013, Journal of the American College of Cardiology.
[2] I. Piña,et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.
[3] J. Z. Gómez,et al. BLOOD HYPEROSMOLARITY AS A PREDICTOR OF MORTALITY IN PATIENTS AFTER ACUTE CORONARY SYNDROME: HOW DEHYDRATION AFFECTS THE PROGNOSIS OF OUR PATIENTS , 2013 .
[4] C. O'connor,et al. Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure , 2013, Circulation. Heart failure.
[5] P. Ponikowski,et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.
[6] Piotr Ponikowski,et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.
[7] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[8] F. Fedele,et al. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations , 2013, Heart Failure Reviews.
[9] K. Anstrom,et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.
[10] C. Ronco,et al. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. , 2012, Journal of the American College of Cardiology.
[11] M. Gheorghiade,et al. The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. , 2012, Journal of cardiac failure.
[12] C. O'connor,et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. , 2012, Journal of cardiac failure.
[13] S. Werns. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .
[14] S. Werns. Diuretic Strategies in Patients with Acute Decompensated Heart Failure , 2012 .
[15] K. Swedberg,et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. , 2011, European heart journal.
[16] P. Ponikowski,et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decom , 2011, Journal of the American College of Cardiology.
[17] Adrian F Hernandez,et al. Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[18] Dirk Westermann,et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. , 2010, Journal of cardiac failure.
[19] P. Ponikowski,et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.
[20] S. Kimmel,et al. Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival , 2010, Circulation.
[21] A. Burger,et al. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. , 2010, Journal of cardiac failure.
[22] P. Ponikowski,et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.
[23] D. Brotman,et al. Usefulness of cystatin C and prognosis following admission for acute heart failure. , 2009, The American journal of cardiology.
[24] J. Burnett,et al. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. , 2009, Journal of the American College of Cardiology.
[25] G. Navis,et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. , 2009, Journal of the American College of Cardiology.
[26] Gary S Francis,et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2009, Journal of the American College of Cardiology.
[27] C. O'connor,et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). , 2008, Journal of cardiac failure.
[28] D. Hodge,et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. , 2008, Journal of cardiac failure.
[29] M. Gheorghiade,et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. , 2008, European heart journal.
[30] U. Elkayam,et al. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action , 2008, Circulation.
[31] S. Werns. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure , 2008 .
[32] R. Witteles,et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. , 2007, Journal of the American College of Cardiology.
[33] B. Massie,et al. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. , 2007, Journal of the American College of Cardiology.
[34] T. Sundt,et al. Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study , 2007, Circulation.
[35] D. J. Veldhuisen,et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction , 2007, European journal of heart failure.
[36] G. Fonarow,et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.
[37] N. Smedira,et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial. , 2007, Journal of the American College of Cardiology.
[38] P. Seferovic,et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. , 2006, European heart journal.
[39] M. Redfield,et al. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. , 2006, Journal of the American College of Cardiology.
[40] Harlan M Krumholz,et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.
[41] Joseph Beyene,et al. Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death , 2005, Annals of Internal Medicine.
[42] M. Fisher,et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine , 2004, Circulation.
[43] C. O'connor,et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. , 2003, American heart journal.
[44] H. Krumholz,et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? , 2002, Journal of cardiac failure.
[45] V. Dharnidharka,et al. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] C. O'connor,et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.
[47] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[48] P. Poole‐Wilson. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002 .
[49] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[50] Horng H. Chen,et al. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. , 1999, Proceedings of the Association of American Physicians.
[51] M. Epstein,et al. Potential of dopamine A-1 agonists in the management of acute renal failure. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] Y. Moshkovitz,et al. Increased toxicity of high‐dose furosemide versus low‐dose dopamine in the treatment of refractory congestive heart failure , 1997, Clinical pharmacology and therapeutics.
[53] P. Varriale,et al. The benefit of low‐dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: Does it protect renal function? , 1997, Clinical cardiology.
[54] M. Redfield,et al. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. , 1989, The American journal of physiology.
[55] L. I. Goldberg,et al. Cardiovascular and renal actions of dopamine: potential clinical applications. , 1972, Pharmacological reviews.
[56] A. Little,et al. American Heart Association: Council on Arteriosclerosis , 1960 .
[57] F. R. Winton,et al. The influence of venous pressure on the isolated mammalian kidney , 1931, The Journal of physiology.